CCP
TEVA icon

Corient Capital Partners’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Corient Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,242
Closed -$98K – 768
2021
Q4 		$98K Sell
12,242
-1,512
-11% -$13.6K 0.01% 696
2021
Q3 		$134K Buy
+13,754
New +$129K 0.01% 669

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Abrams Capital Management
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Menora Mivtachim Holdings
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
Migdal Insurance & Financial Holdings
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Clal Insurance
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Phoenix Financial
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Harel Insurance Investments & Financial Services
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Corient Capital Partners's TEVA Position: Q1 2022 in Review

Corient Capital Partners sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2022, closing a stake of 12,242 shares — an estimated $98K sold.

Corient Capital Partners first reported a position in TEVA in Q3 2021 and held it in 2 quarters. The position peaked at $134K in Q3 2021. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Corient Capital Partners reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2022 after selling out during the quarter.
  • Corient Capital Partners sold 12,242 Teva Pharmaceutical Industries Limited shares in Q1 2022, an estimated $98K.
  • Corient Capital Partners first reported a position in Teva Pharmaceutical Industries Limited in Q3 2021 and held it in 2 quarters.
  • Corient Capital Partners's Teva Pharmaceutical Industries Limited position peaked at $134K in Q3 2021.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2022.

Based on Corient Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.